Probiotics – a sword or a shield in COVID-19 outcome?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/27165 |
Resumo: | How extensively frenzy could a viral infection cause? The virus of the betacoronavirus family, SARS-CoV-2, agent of COVID-19, has shaken economic and health structures around the world since the end of 2019. There are several attempts to prevent the spread of this virus, from effective sanitary measures, or the "gold rush" for drug repositioning, to the accelerated development of vaccines. In this sense, the empirical use of antibiotics has increased even more in hospitalized patients to avoid bacterial coinfections, which could be an aggravating factor in unfavorable clinical outcomes. However, the non-rational use of these drugs, in addition to contributing to the emergence of multidrug-resistant microorganisms, can contribute to a worrying situation, intestinal dysbiosis, an event with "pleiotropic" proportions, which can significantly worsen SARS- CoV-2. Different studies report that hospitalized patients with COVID-19 have shown a reduction in the population of probiotic butyrate-producing bacteria, such as Faecalibacterium prausnitzii, in addition to a reduction in the Firmicute/Bacteroidetes ratio and an increase in the proportion of Actinobacteria, among other opportunistic pathogens. This imbalance in the gut microbiota has been correlated with increased pro-inflammatory biochemical indicators and reduced anti-inflammatory drugs, which contribute to unfavorable outcomes. Thus, understanding the harmonic and disharmonious microbial interactions in the context of COVID-19 can help develop non-pharmacological strategies capable of modulating the host response and avoiding complications, particularly concerning patients with comorbidities. |
id |
UNIFEI_f4cffb59e789a1029de88a5a528836ce |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/27165 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Probiotics – a sword or a shield in COVID-19 outcome?Probióticos: ¿una espada o un escudo en el resultado de COVID-19?Probióticos – uma espada ou um escudo no desfecho da COVID-19?MicrobiotaCOVID-19DisbioseUso racional de antibacterianos. MicrobiotaDysbiosisCOVID-19Rational use of antibiotics.MicrobiotaDisbiosisCOVID-19Uso racional de antibióticos.How extensively frenzy could a viral infection cause? The virus of the betacoronavirus family, SARS-CoV-2, agent of COVID-19, has shaken economic and health structures around the world since the end of 2019. There are several attempts to prevent the spread of this virus, from effective sanitary measures, or the "gold rush" for drug repositioning, to the accelerated development of vaccines. In this sense, the empirical use of antibiotics has increased even more in hospitalized patients to avoid bacterial coinfections, which could be an aggravating factor in unfavorable clinical outcomes. However, the non-rational use of these drugs, in addition to contributing to the emergence of multidrug-resistant microorganisms, can contribute to a worrying situation, intestinal dysbiosis, an event with "pleiotropic" proportions, which can significantly worsen SARS- CoV-2. Different studies report that hospitalized patients with COVID-19 have shown a reduction in the population of probiotic butyrate-producing bacteria, such as Faecalibacterium prausnitzii, in addition to a reduction in the Firmicute/Bacteroidetes ratio and an increase in the proportion of Actinobacteria, among other opportunistic pathogens. This imbalance in the gut microbiota has been correlated with increased pro-inflammatory biochemical indicators and reduced anti-inflammatory drugs, which contribute to unfavorable outcomes. Thus, understanding the harmonic and disharmonious microbial interactions in the context of COVID-19 can help develop non-pharmacological strategies capable of modulating the host response and avoiding complications, particularly concerning patients with comorbidities.¿Cuánto frenesí podría causar una infección viral? El virus de la familia de los betacoronavirus, SARS-CoV-2, agente del COVID-19, ha sacudido las estructuras económicas y sanitarias de todo el mundo desde finales de 2019. Son varios los intentos de evitar la propagación de este virus, a partir de medidas sanitarias eficaces , o la "fiebre del oro" por el reposicionamiento de fármacos, hasta el desarrollo acelerado de vacunas. En este sentido, se ha incrementado aún más el uso empírico de antibióticos en pacientes hospitalizados para evitar las coinfecciones bacterianas, lo que podría ser un factor agravante de desenlaces clínicos desfavorables. Sin embargo, el uso no racional de estos fármacos, además de contribuir a la aparición de microorganismos multirresistentes, puede contribuir a una situación preocupante, la disbiosis intestinal, un evento de proporciones "pleiotrópicas", que puede empeorar significativamente el SARS-CoV- 2. Diferentes estudios reportan que pacientes hospitalizados con COVID-19 han mostrado una reducción en la población de bacterias probióticas productoras de butirato, como Faecalibacterium prausnitzii, además de una reducción en la relación Firmicute/Bacteroidetes y un aumento en la proporción de Actinobacteria, entre otros patógenos oportunistas. Este desequilibrio en la microbiota intestinal se ha correlacionado con un aumento de los indicadores bioquímicos proinflamatorios y una reducción de los fármacos antiinflamatorios, lo que contribuye a resultados desfavorables. Por lo tanto, comprender las interacciones microbianas armónicas y disarmónicas en el contexto de COVID-19 puede ayudar a desarrollar estrategias no farmacológicas capaces de modular la respuesta del huésped y evitar complicaciones, particularmente en pacientes con comorbilidades.Quanto frenesi uma infecção viral poderia causar? O vírus da família de betacoronavirus, SARS-CoV-2, agente da COVID-19, abala estruturas econômica e sanitária em todo o mundo desde final de 2019. São inúmeras as tentativas de impedir a expansão deste vírus, sejam através de medidas sanitárias efetivas, ou na "corrida do ouro" por reposicionamento de fármacos e desenvolvimento acelerado de vacinas. Neste sentido, o uso empírico de fármacos como os antibióticos aumentaram ainda mais em pacientes hospitalizados, na tentativa de evitar coinfecções bacterianas, o que poderia ser um agravante nos desfechos clínicos desfavoráveis. No entanto, o uso não racional destes medicamentos, além de contribuírem para o surgimento de micro-organismos multirresistentes, podem contribuir para um quadro preocupante, a disbiose intestinal, um evento com proporções "pleiotrópicas", que pode agravar demasiadamente a infecção por SARS-CoV-2. Diferentes estudos relatam que pacientes hospitalizados com COVID-19 vêm apresentando redução populacional de bactérias probióticas produtoras de butirato, como Faecalibacterium prausnitzii, além da redução na razão Firmicute/Bacteroidetes e aumento da proporção de Actinobacterias, entre outros patógenos oportunistas. Este desequilíbrio na microbiota intestinal tem sido correlacionado à elevação dos níveis de indicadores bioquímicos pró-inflamatórios e redução dos anti-inflamatórios, os quais contribuem para desfechos desfavoráveis. Destarte, compreender as interações microbianas harmônicas e desarmônicas no contexto da COVID-19, podem auxiliar no desenvolvimento de estratégias não farmacológicas, capazes de modular a resposta do hospedeiro e evitar complicações, particularmente no tocante aos pacientes com comorbidades.Research, Society and Development2022-03-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/2716510.33448/rsd-v11i4.27165Research, Society and Development; Vol. 11 No. 4; e11011427165Research, Society and Development; Vol. 11 Núm. 4; e11011427165Research, Society and Development; v. 11 n. 4; e110114271652525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/27165/23718Copyright (c) 2022 Joel Antonio Cordeiro de Abreu; Natália Lopes de Freitas; Pedro Ricardo G Azevedo; Fabiana Brandãohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessAbreu, Joel Antonio Cordeiro de Freitas, Natália Lopes de Azevedo, Pedro Ricardo GBrandão, Fabiana2022-03-27T17:17:09Zoai:ojs.pkp.sfu.ca:article/27165Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:44:59.033992Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Probiotics – a sword or a shield in COVID-19 outcome? Probióticos: ¿una espada o un escudo en el resultado de COVID-19? Probióticos – uma espada ou um escudo no desfecho da COVID-19? |
title |
Probiotics – a sword or a shield in COVID-19 outcome? |
spellingShingle |
Probiotics – a sword or a shield in COVID-19 outcome? Abreu, Joel Antonio Cordeiro de Microbiota COVID-19 Disbiose Uso racional de antibacterianos. Microbiota Dysbiosis COVID-19 Rational use of antibiotics. Microbiota Disbiosis COVID-19 Uso racional de antibióticos. |
title_short |
Probiotics – a sword or a shield in COVID-19 outcome? |
title_full |
Probiotics – a sword or a shield in COVID-19 outcome? |
title_fullStr |
Probiotics – a sword or a shield in COVID-19 outcome? |
title_full_unstemmed |
Probiotics – a sword or a shield in COVID-19 outcome? |
title_sort |
Probiotics – a sword or a shield in COVID-19 outcome? |
author |
Abreu, Joel Antonio Cordeiro de |
author_facet |
Abreu, Joel Antonio Cordeiro de Freitas, Natália Lopes de Azevedo, Pedro Ricardo G Brandão, Fabiana |
author_role |
author |
author2 |
Freitas, Natália Lopes de Azevedo, Pedro Ricardo G Brandão, Fabiana |
author2_role |
author author author |
dc.contributor.author.fl_str_mv |
Abreu, Joel Antonio Cordeiro de Freitas, Natália Lopes de Azevedo, Pedro Ricardo G Brandão, Fabiana |
dc.subject.por.fl_str_mv |
Microbiota COVID-19 Disbiose Uso racional de antibacterianos. Microbiota Dysbiosis COVID-19 Rational use of antibiotics. Microbiota Disbiosis COVID-19 Uso racional de antibióticos. |
topic |
Microbiota COVID-19 Disbiose Uso racional de antibacterianos. Microbiota Dysbiosis COVID-19 Rational use of antibiotics. Microbiota Disbiosis COVID-19 Uso racional de antibióticos. |
description |
How extensively frenzy could a viral infection cause? The virus of the betacoronavirus family, SARS-CoV-2, agent of COVID-19, has shaken economic and health structures around the world since the end of 2019. There are several attempts to prevent the spread of this virus, from effective sanitary measures, or the "gold rush" for drug repositioning, to the accelerated development of vaccines. In this sense, the empirical use of antibiotics has increased even more in hospitalized patients to avoid bacterial coinfections, which could be an aggravating factor in unfavorable clinical outcomes. However, the non-rational use of these drugs, in addition to contributing to the emergence of multidrug-resistant microorganisms, can contribute to a worrying situation, intestinal dysbiosis, an event with "pleiotropic" proportions, which can significantly worsen SARS- CoV-2. Different studies report that hospitalized patients with COVID-19 have shown a reduction in the population of probiotic butyrate-producing bacteria, such as Faecalibacterium prausnitzii, in addition to a reduction in the Firmicute/Bacteroidetes ratio and an increase in the proportion of Actinobacteria, among other opportunistic pathogens. This imbalance in the gut microbiota has been correlated with increased pro-inflammatory biochemical indicators and reduced anti-inflammatory drugs, which contribute to unfavorable outcomes. Thus, understanding the harmonic and disharmonious microbial interactions in the context of COVID-19 can help develop non-pharmacological strategies capable of modulating the host response and avoiding complications, particularly concerning patients with comorbidities. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-03-12 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/27165 10.33448/rsd-v11i4.27165 |
url |
https://rsdjournal.org/index.php/rsd/article/view/27165 |
identifier_str_mv |
10.33448/rsd-v11i4.27165 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/27165/23718 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 11 No. 4; e11011427165 Research, Society and Development; Vol. 11 Núm. 4; e11011427165 Research, Society and Development; v. 11 n. 4; e11011427165 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052706937896960 |